Thermo Fisher Scientific Inc (TMO)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	5,995,000	5,941,000	4,200,000	4,503,000	3,188,000	3,270,000	5,198,000	5,362,000	5,191,000	6,031,000	6,062,000	5,390,000	6,375,000	6,912,000	5,739,000	5,702,000	5,729,000	5,618,000	5,567,000	5,200,000
Total stockholders’ equity	US$ in thousands	46,735,000	45,328,000	43,752,000	42,257,000	43,978,000	43,549,000	42,293,000	40,956,000	40,793,000	38,710,000	36,854,000	35,058,000	34,507,000	31,824,000	29,875,000	28,559,000	29,675,000	29,355,000	28,729,000	27,693,000
ROE		12.83%	13.11%	9.60%	10.66%	7.25%	7.51%	12.29%	13.09%	12.73%	15.58%	16.45%	15.37%	18.47%	21.72%	19.21%	19.97%	19.31%	19.14%	19.38%	18.78%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $5,995,000K ÷ $46,735,000K
= 12.83%

Thermo Fisher Scientific Inc.'s return on equity (ROE) has shown a declining trend over the past eight quarters, starting at 18.56% in Q1 2022 and decreasing to 12.83% in Q4 2023. This indicates a decrease in the company's ability to generate profit from its shareholders' equity over the period under review. The downward trend in ROE may raise concerns among investors and stakeholders, as it suggests a decrease in the company's profitability and efficiency in utilizing equity to generate returns. Further analysis is recommended to identify the factors contributing to this decline in ROE and to formulate appropriate strategies to improve the company's performance in the future.